Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.

Bensimon, Arielle G; Zhou, Zheng-Yi; Jenkins, Madeline; Song, Yan; Gao, Wei; Signorovitch, James; Krepler, Clemens; Liu, Frank Xiaoqing; Wang, Jingshu; Aguiar-Ibáñez, Raquel.
J Med Econ; : 1-13, 2019 Apr 23.
Artigo em Inglês | MEDLINE | ID: mdl-31012765